DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics

DIAsource ImmunoAssays SA (Louvain-La-Neuve, Belgium), which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH (Viro-Immun Diagnostics GmbH), a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.

DIAsource manufactures and sells manual kits and open automation for clinical diagnostics, while Viro-Immun offers a portfolio of assays in infectious and autoimmune diseases, including the ToRCH panel with parameters such as Toxoplasma, Rubella, Herpes. With this transaction, DIAsource has acquired the Viro-Immun brand name and all ELISA and IFA products, as well as full inventory and infrastructure, thereby further strengthening and extending its portfolio of endocrinology and Vitamin D products. The acquisition of Viro-Immun fits in with DIAsource's strategy to act as a consolidator in its core business of manual kits and open automation.

Effective September 5, 2017, BioVendor - Laboratornímedicínaa.s. (Brno, Czech Republic) acquired 100% of the shares of DIAsource from Anteo Diagnostics (Queensland, Australia), which had acquired DIAsource in January 2016. The acquisition of DIAsource extended BioVendor’s broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, as well as established a direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries.